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1. Introduction 
The dramatic clinical presentation of many seizure disorders has been recognized for 
millennia. Many prominent individuals have been affected including Julius Caesar, James 
Madison, Peter Tchaikovsky, Alfred Nobel and Leo Tolstoy. Distinguishing types of seizures 
has helped direct treatment, clarify prognosis and, more recently, provide insight into basic 
pathophysiology. Clearly, the generic “seizure” involves neuronal dysfunction. Often, there 
are no physical changes in brain cells. Nutritional and toxic aspects of seizures have been 
studied in past decades. Perhaps more valuable in terms of cellular biology have been insights 
gained from examination of well-defined seizure types. Of particular interest has been a group 
of neuromuscular disorders genetically linked to the mitochondrial genome. 
2. Mitochondrial genetic 
Mitochondria are the powerhouses of our cells. They are responsible for heat production 
and generating energy as adenosine triphosphate (ATP), therefore  mitochondria play a 
major role in initiating the process of apoptosis. Mitochondria produce more than 90% of 
our cellular energy by oxidative phosphorylation (OXPHOS) (Wallace D.C, 1999 and 2005, 
Gupta, 2001, Spees, J et al 2006) (DiMauro, S., Schon, E. A. 2003). Energy production is the 
result of two closely coordinated metabolic processes including the tricarboxylic acid (TCA) 
cycle, also known as the Krebs or citric acid cycle, and the electron transport chain (ETC). 
The TCA cycle converts carbohydrates and fats into some ATP, but its major job is the 
capture of electrons by the coenzymes NADH and FADH which shuttle this energy to the 
ETC. The synthesis of ATP occurs through the respiratory which is located at the inner 
mitochondrial membrane and consists of five protein complexes (Complexes I–V). Most of 
the oxygen that is consumed that reduced to water through four consecutive one-electron 
reductions. (Brookes, P et al. 2004). Current theory holds that mitochondria are the 
descendants of aerobic bacteria that colonized an ancient prokaryote between 1 and 3 billion 
years ago (Vellai T et al. 1998 and Roger AJ et al. 1996). 
A single somatic cell can contain from of 200 to 2000 mitochondria  (Veltri K et al 1990 and 
Gray M.W, et al 1989), while human germ cells such as spermatozoa contain a fixed number 
of 16 mitochondria and oocytes have up to 100000 (Szewczyk A et al 2002). The largest 
numbers of mitochondria are found in the most metabolically active cells, such as skeletal, 
cardiac muscle, the liver and brain. Mitochondria are found in every human cell except 
mature erythrocytes (Cohen, B. H., and Gold, D. R. 2001). 
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Mitochondria are controlled by both nuclear and mitochondrial genomes therefore, there are 
several very unique features of the mitochondrial genome. Mitochondrial DNA comprises 0.1–
2% of the total DNA in most mammalian cells. MtDNA consists of a 16.5 kb doublestranded 
circular DNA molecule that is maternally inherited (Anderson et al. 1981). MtDNA has 2 
strands: a guanine-rich heavy strand (or outer strand) and cytosine-rich light strand (or inner 
strand). The comprision of  ETC 13 polypeptide genes can be classified as fallow: 
1.  MtDNA also encodes the 12S and 16S rRNA genes, and the 22 tRNA genes, which are 
required for mitochondrial protein synthesis. MtDNA encodes 7 subunits (ND1, 2, 3, 4, 
4L, 5, and 6) of the 46 subunits constituting complex I, one of 11 subunits of complex III, 
3 of 13 subunits of complex IV, and 2 of 17 subunits of complex V (Reddy PH and Beal 
MF, 2005).  The rest of the polypeptides of the ETC complexes, including all the 
subunits of Complex II (succinate dehydrogenase), as well as approximately 1500 other 
proteins which function in mitochondria are encoded by nuclear genes, synthesized in 
the cytosol and imported into mitochondria through various protein import systems.  
2.  Genetic information is not distributed equally on the two mtDNA strands. The two 
mtDNA strands can be separated by denaturing cesium chloride gradient 
centrifugation (Kasamatsu H, and Vinograd J, 1974). Most of the information is encoded 
in the heavy (purine-rich) strand. The light (pyrimidine-rich) strand contains genetic 
information for only one polypeptide and eight tRNAs.  
3.  Mitochondrial genes have no introns and intergenic sequences are absent or limited to 
a few bases. Some genes overlap and in some instances, termination codons are not 
encoded (Ojala D, et al., 1981).  
4. Human mtDNA is exclusively inherited through the maternal lineage. Mitochondria from 
spermatozoa penetrate to the ovum but they are selectively marked with ubiquitin and 
apparently removed (Sutovsky P et al.1999). It has been recently found that even before 
the elimination of the spermatozoa mitochondria, the mtDNA is degraded (Nishimura Y. 
et al. 2006).Spermatozoa are germinal cells but the behavior of their mitochondria is 
similar to that of somatic cells. They are very active (E. Ruiz-Pesini  et al 2007)and produce 
many mutagenic reactive oxygen species (ROS). Thus, by removing the paternal mtDNA, 
the possibility of transmitting mtDNA mutations decreases enormously. In fact, the only 
known human paternal contribution to the next generation is associated with a pathologic 
mutation in the mtDNA (M. Schwartz  et al 2002). 
5. Mitochondria do not have histones. However, mammalian mtDNA is organized in 
nucleoids, which can be seen under the microscope as punctuate structures containing 
mtDNA and proteins which localize to the matrix surface of the mitochondrial inner 
membrane. Another important piece of information about mtDNA is whether this 
genome is totally dependent upon nuclear-encoded proteins for its maintenance and 
transcription. Regarding replication, mtDNA replicates throughout the lifespan of an 
organism in both proliferating and post-mitotic cells in order to maintain a constant 
supply of genetic material so that mitochondria can undergo continuous turnover.  
6. Mammalian mitochondria have multi-copies of own genome (approximately 103 to 104 
copies/cell). Mitochondria which is replicated and expressed within mitochondria 
(Clayton, 1982, 1984).  
7. While the ovum has about 100,000 copies of mtDNA, during oogenesis, the number of 
mtDNA molecules that will populate the next generation is very small, with estimates 
ranging as low as one to a few mtDNA genomes (known as the “bottleneck”) (Wallace 
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DC, et al 2001and Howell N, et al 2000). Thus, a heteroplasmic mother frequently will 
have children with widely different average levels of mutant heteroplasmy. 
8. Unlike nuclear genes in which there are usually two copies per cell, mtDNA is at high 
copy number with hundreds to tens of thousands of copies per cell (Smeitink J, et al 
2001). Thus, while in nuclear genetics there are homozygotes (100% mutant) and 
heterozygotes (50% mutant) within mtDNA, mutant proportions can vary anywhere 
between 0% and 100% across the spectrum (e.g., 0.42% or 78.3% mutant). When two 
(and very rarely more) mtDNA sequences coexist in the same mitochondrion, cell, 
tissue or individual, the term “heteroplasmy” is applied.  In clinical diagnostics, one 
usually discusses heteroplasmy as consisting of a “wild-type” (normal) mtDNA 
sequence and a “mutant”  (disease-associated) mtDNA sequence, although this is not 
always the case as benign polymorphisms can also be heteroplasmic, in other words, 
both mtDNA sequences may be unrelated to disease (Tzen CY, et al 2001). 
9. A critical number of mutated mtDNAs must be present before tissue dysfunction and 
clinical signs become apparent, so-called threshold effect. Tissues with high 
requirements for oxidative energy metabolism, such as muscle, heart, brain, and 
neurosensory organs have relatively low thresholds and are particularly vulnerable to 
mtDNA mutations. 
3. Mitochondrial disorders 
Hereditary mitochondrial disorders are caused by mutations in the mtDNA, or nuclear 
DNA (nDNA), resulting in impaired respiratory chain activity or oxidative phosphorylation. 
Phenotypically, mitochondrial disorders present as single or multi system diseases, with 
onset between birth and senescence (Zeviani M, Di DonatoS  2004).  Mitochondrial disorders 
usually have a progressive course which is why single organ affection turns into multi-
system affection during the disease course. Mitochondrial disorders manifest in 
tissues/organs with high-energy demand (Montirosso R, et al.2002) and are aggravated by 
fever, infection, stress, or certain drugs (Longo N. 2003). Systems/organs most frequently 
clinically or sub-clinically affected in mitochondrial disorders are the peripheral nervous 
system, the central nervous system (CNS), endocrine glands, heart, ears, eyes, 
gastrointestinal tract, liver, kidneys, bone marrow, and dermis (Finsterer J. 2004).Various 
combinations of organ affection constitute mitochondrial syndromes for which well-known 
acronyms have been adopted. 
The second most frequently affected system is the CNS (Finsterer J et al 2001). Similar to 
other organs, the CNS may be affected alone or together with one or several other tissues. 
Most frequently the CNS is affected together with the skeletal muscles for which the term 
_encephalomyopathy_ was coined (Riggs JE, et al 1984,  Leonard JV, Schapira AHV 2000).  
The frequency of mtDNA diseases is high. It has been estimated that one out of 
approximately 8000 individuals harbors a pathogenic mtDNA mutation (Chinnery P.F. et al 
2000). Mitochondrial diseases are mostly caused by defects in the enzymes involved in 
respiration and OXPHOS (Wallace D.C, 1999 and 2005, Gupta, 2001, Spees, J et al 2006, 
DiMauro, S., Schon, E. A 2003). They may arise from mutations in nuclear DNA or mtDNA. 
It has been documented that some mitochondrial diseases are caused by specific mutations 
in nuclear genes, which are involved in the replication and maintenance of mtDNA and 
respiratory chain function of mitochondria. These diseases may be resulted from defects in 
the citric acid cycle, ǃ-oxidation of fatty acids, the urea cycle, and the respiration and 
OXPHOS system, respectively. 
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A striking feature of mtDNA disorders is their clinical heterogeneity, ranging from single-
organ involvement to severe multisystem disease. The same mutation or different mutations 
in the same mtDNA gene may present with very different clinical manifestations while the 
same clinical phenotype may be caused by different mutations. 
This variability in clinical manifestation may be due to several factors, including the ratio of 
wild-type to mutant mtDNA, varying thresholds of biochemical expression for both the 
mutation and the tissue involved, and the modulating effect of nuclear and other 
mitochondrial genes. Since 1988, more than 100 distinct mtDNA point mutations have been 
identified in patients with diverse clinical phenotypes (Schon EA, et al 2002. and Servidei S, 
2002). 
 
Organ 
system 
Possible symptom or disease 
Muscles Hypotonia, weakness, cramping, muscle pain, ptosis, opthalmoplagia 
Brain Developmental delay, mental retardation, autism, dementia, seizures, 
neuropsychiatric disturbances, atypical cerebral palsy, atypical migraines, 
autism, and stroke like events  
Nerves Neuropathic pain and weakness, acute and chronic inflammatory 
demyelinating polyneuropathy, absent deep tendon  reflexes, neuropathic 
gastrointestinal problem, fainting, absent or excessive sweating aberrant 
temperature regulation 
Kidneys Proximal renal tubular dysfunction: possible loss of protein, magnesium, 
phosphorus, calcium, and other electrolytes 
Heart Cardiac conduction defects, cardiomyopathy 
Liver Hypoglycemia, gluconeogenic defects, nonalcoholic liver failure 
Eyes Optic neuropathy and retinitis pigmentosa 
Ears Sensorineural hearing loss, aminoglycoside sensitivity 
Pancreas Diabetes and exocrine pancreatic failure  
Systemic Failure to gain weight, short stature, fatigue, respiratory problems 
including intermittent air hunger 
Table 1. Signs, symptoms and diseases associated with mitochondrial dysfunction 
Myopathies  
1. Chronic progressive external ophthalmoplegia (CPEO), with or without retinitis 
pigmentosa or limb weakness and fatigue, is the commonest clinical manifestation of an 
OXPHOS mtDNA defect. The age of onset is usually during the second or third decades 
but late-onset mitochondrial myopathy is well recognized. The clinical course is usually 
benign in that additional tissue or organ failure rarely develops and the risk of serious 
disability is very low.  
2. Kearns–Sayre syndrome (KSS) is a subtype of CPEO with onset before age 20 and one of 
the following: cardiac conduction defects, cerebellar ataxia or CSF protein greater than 
100 mg/dl. Some patients have additional manifestations, including dementia or 
endocrinopathies. These patients may develop additional features such as deafness, 
diabetes, endocrine dysfunction, and behavioural disorders. The prognosis is much 
worse than that for isolated CPEO, and few patients survive beyond the age of 30. 
Isolated limb myopathy is a frequent manifestation of mtDNA disorders, taking the 
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form of a proximal limb weakness with fatigue. Deterioration is usual but it is slow and 
the patient is unlikely to need a wheelchair. This spectrum of phenotypes is often 
caused by a single large mtDNA deletion, especially the 5-kb “common deletion”, but 
additional possibilities include deletion/duplications and mtDNA point mutations 
including A3243G (Wallace DC, et al 2001). 
Leber’s hereditary optic neuropathy (LHON) 
1. LHON is the commonest cause of blindness in healthy young men. It is maternally 
inherited and manifests in late adolescence or early adulthood as bilateral sequential 
visual failure. 90% of patients are affected by age 40 and virtually all by age 50. 
Although the disease is usually confined to the optic nerve some patients also have 
cardiac conduction defects or encephalopathic features, particularly dystonia. The 
preponderance of males (about 80%) among LHON patients and the high proportion of 
symptomless carriers have prompted the suggestion that factors other than mtDNA 
mutations contribute to pathogenesis. LHON is usually caused by homoplasmic 
mtDNA mutations (100% mutant); the most common are G11778A, G3460A and 
T14484C (Wallace DC, et al 2001). Penetrance is low, and males are three to four times 
more likely to become blind than females. 
Encephalomyopathies 
Any combination of encephalopathic features (dementia/mental retardation, ataxia, 
seizures, myoclonus, deafness, dystonia) may occur alone, in combination, or in association 
with myopathy. However, certain syndromes have emerged that remain a useful means for 
classification even though the syndromes may overlap considerably. 
1. Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is 
probably the commonest of the mitochondrial encephalomyopathies. This syndrome is 
characterized by stroke-like episodes, often reversible, with onset generally between 
age 5–15 years but can be anywhere between infancy and adulthood. Most cases are 
caused by heteroplasmy for the A3243G mutation; however, T3271C, other 
heteroplasmic mtDNA point mutations, large rearrangements and presumed nuclear 
defects (with normal mtDNA) can cause the MELAS phenotype. Ragged-red fibers and 
abnormal electron transport chain activities are frequently absent, particularly in 
younger children. Although the A3243G mutation is usually thought of as being causal 
for MELAS, the mutation is more often associated with maternally inherited diabetes, 
deafness, cognitive impairment, short stature and/or migraine, as well as a wide 
variety of other disease manifestations (Wallace DC, et al 200; Shah NS, et al 2002; 
Harrison TJ, et al  1997; and Majamaa K, et al  1998). 
2. Leigh syndrome Also called subacute necrotizing encephalopathy, this disorder is 
characterized by cranial nerve abnormalities, respiratory dysfunction and ataxia with 
hyperintense signals on T2-weighed images in the basal ganglia, cerebellum or brain 
stem. Age of onset is from infancy to early childhood. As in many other mitochondrial 
disorders, Leigh disease is usually but not always progressive and lethal, and 
progression often occurs associated with infection. There is significant genetic 
heterogeneity, including mutations on both genomes. Very high mutant loads of the 
T8993G/C mtDNA mutation (usually > 95%) are one common cause of Leigh 
syndrome. The most common nuclear DNA related causes of Leigh disease are complex 
I deficiency (including NDUFV1 mutations), complex IV deficiency (including SURF1 
mutations), and PDHC deficiency (Wallace DC, et al 2001). 
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3. Myoclonic epilepsy and ragged-red fiber disease (MERRF) this syndrome consists of 
progressive epilepsy and dementia, with onset in late childhood or adulthood. Most 
cases have heteroplasmy for A8344G, a point mutation in the tRNA lysine gene. Some 
patients have multiple symmetrical lipomatosis, which are large subcutaneous fat 
masses, usually located around the neck (Shoffner JM. 2001). Ragged-red fibers refer to 
subsacrolemmal collections of mitochondria that stain red on modified Gomori 
trichrome stain. They are present in many patients with different presentations of 
mitochondrial disease but are not common in affected children. Myoclonus may occur 
in association with generalized seizures. The prognosis is variable but a useful pointer 
is the mutant load in the blood.  
 
Syndrome Symptom
Kearn-Sayre Syndrome (KSS) External ophtalmoplegia, cardiac conduction 
defects, and sensorineural hearing loss 
Leber hereditary optic neuropathy 
(LHON) 
Visual loss in young adulthood
Mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like 
syndrome (MELAS) 
Varying degrees of cognitive impairment and 
dementia, lactic acidosis, strokes, and transient 
ischemic attacks 
Myoclonic epilepsy and ragged-red 
fibers (MEERF) 
Progressive myoclonic epilepsy, clumps of 
diseased mitochondria accumulate in the 
subsarcolemmal of the muscle fibers 
Leigh syndrome subacute sclerosis 
encephalopathy 
Seizures, altered states of consciousness, 
dementia, ventilator failure  
Neuropathy, ataxia, retinitis, 
pigmentosa, and ptosis (NARP) 
Dementia, in addition to the symptoms described 
in the acronym 
Myoneurogenic gastrointestinal 
encephalopathy (MINGIE) 
Gastrointestinal pseudo-obstruction, neuropathy 
Table 2. Inherited conditions in which mitochondrial dysfunction has been implicated 
Mitochondrial Investigation 
1. Biochemistry: Blood lactate concentrations and lactate: pyruvate ratios may be increased 
at rest and rise significantly above those for matched controls after exercise. In patients 
with encephalopathy, particularly in infants, CSF lactate may be raised. Creatine kinase 
levels are either normal or only mildly increased. Biochemical analysis of isolated 
mitochondria or muscle tissue by enzyme studies, polarography, or spectroscopy may 
identify the site(s) of the defect within the respiratory chain and this can help to direct 
molecular genetic analysis. 
2. Electrophysiology: The electromyogram is normal or only mildly myopathic while nerve 
conduction studies may demonstrate a peripheral (predominantly axonal) neuropathy. 
3. Imaging: Cranial computed tomography demonstrates cerebral and cerebellar atrophy 
in many encephalopathic patients; basal ganglia calcification may be seen in MELAS. 
Magnetic resonance imaging in MELAS-associated stroke reveals increased T2 
weighted signals in the grey and white matter, typically of the occipital or parieto-
occipital areas. Symmetrical changes in the basal ganglia and brainstem are frequently 
observed in those with Leigh syndrome. 
4. Histology: Muscle biopsy is diagnostic, although occasional patients, with mitochondrial 
myopathy due to mtDNA mutations and those with LHON may have normal biopsies. 
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Histochemical analysis typically reveals ragged red fibers on Gomoritrichrome staining 
and these fibers stain strongly for succinate dehydrogenase (SDH, complex II). These 
fibers often stain negatively for COX (complex IV) in CPEO, KSS, or MERRF but 
positively in MELAS. Maternally inherited Leigh syndrome patients or others 
presenting in infancy may have no ragged red fibers and demonstrate COX-negative 
fibers only.  
5. Molecular genetics: Whilst muscle biopsy may prove diagnostic clinically, molecular 
genetic analysis is necessary for genetic counseling. MtDNA rearrangements are not 
usually found in blood whilst point mutations are; both types are seen in muscle. Thus 
a negative result for mutation analysis of mtDNA in blood does not exclude 
mitochondrial OXPHOS disease. Single mtDNA deletion is the commonest mutation 
identified in patients presenting in adolescence or adulthood. These mutations are seen 
most frequently in CPEO with or without myopathy and in KSS although they may 
occasionally be identified in patients with other phenotypes, including MELAS. 
mtDNA duplications often accompany deletions and may represent an intermediate 
stage from the wild-type molecule to deletion although their pathogenicity is uncertain. 
mtDNA tRNA mutations are probably the commonest of the single base change 
abnormalities. A3243G (A->G transition at bp 3243) in the tRNALeu(UUR) gene is most 
frequently found in MELAS and G8344A in tRNALys in MERRF. Many other tRNA 
mutations have been associated with other clinical phenotypes. Again, there is no strict 
relation between phenotype and genotype. The primary mutations associated with 
LHON (G11778A, G3460A, T14484C) are in complex I genes ND4, ND1, and ND6, 
respectively. G11778A is by far the commonest mutation and is found in over 50% of 
LHON families in the UK. A variety of secondary mutations may cause LHON if 
present in combination but only the primary ones seem capable of causing LHON on 
their own. The mutations are distributed in all tissues and are present in blood in high 
load, often being homoplasmic. 
However, a systematic search for new mtDNA mutations is usually undertaken only in 
highly selected patients, when there is a strong indication that symptoms are attributable to 
a mitochondrial defect and the trait is transmitted maternally (Houshmand et al 1994) 
 
Phenotype Mutation Gene 
LHON 3460 G->A MT-ND1 
 11778 G->A MT-ND4 
 14484 T->C MT-ND6 
Leigh, NARP 8993 T->G MT-ATP 6 
MELAS, Diabetes 3243 A->G MT- TL1 
MERRF 8344 A->G MT-TK 
Non syndromic deafness 1555 A->G MT-RNR1 
Table 3. Mitochondrial DNA Mutations frequently associated to specific phenotype 
MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org 
4. Mitochondrial epilepsy 
The genetic forms of progressive myoclonus epilepsies (PMEs) are a clinically variable and 
causally rare heterogenous group, mostly autosomal recessive disorders. The exceptions to 
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autosomal recessive mode of inheritance are autosomal dominant dentatorubral-
pallidoluysian atrophy and MERRF. 
 
Model Samples Experimental findings Reference 
kainic acid, 
 -treated rats 
Hippocampal 
slices 
Increased basal energy 
turnover with glucose as 
substrate Higher uncoupled 
rate of respiration
Kunz  
et al.( 1999 
Temporal lobe 
epilepsy (human) 
Hippocampal 
specimens 
Mitochondrial Complex I 
deficiency and ultrastructural 
abnormalities of 
mitochondria in the epileptic 
focus
Kunz  
et al.(2000 
Perforant path 
stimulation model 
of rats 
Whole brain 
tissues 
 
Reduction of brain aconitase 
and <-ketoglutarate dehydro 
genase activities 
Decrease in reduced 
glutathione levels
Cock  
et al.(2002 
 
Pilocarpine-treated
rats 
Hippocampal 
tissues and 
slices 
Decline of the activities of 
Complexes I and IV and 
lower 
mitochondrial membrane 
potential in CA1 and CA3 
sub 
fields 
Decrease in mitochondrial 
DNA copy number in CA3
Kudin  
et al.(2002 
  
Perforant path 
stimulation model 
of rats 
Hippocampal 
tissues 
 
Reductions in glutathione, <-
ketoglutarate dehydrogenase, 
aconitase, citrate synthase, 
and Complex I activities
Gibbs  
et al.(2006 
Pilocarpine-treated
rats 
Hippocampal 
tissues 
Depression of mitochondrial-
and nuclear-encoded COX 
activity and COX III 
expression 
Mitochondrial ultrastructural 
damage
Gao  
et al.(2007 
 
Intracerebroventricular
infusion of 
homocysteic 
acid in rats 
Cerebral 
cortex 
 
Mitochondrial Complex I 
inhibition 
 
Folbergrová 
et al.(2007 
 
Microinjection of KA
into the hippocampus 
of rats 
Hippocampal 
tissues 
 
Dysfunction of Complex I in 
the mitochondrial electron 
transport chain and 
mitochondrial ultrastructural 
injury 
Chuang  
et al.(2004 
 
 
Tabela 4. Evidences of mitochondrial dysfunction following epileptic seizures from animal 
and human studies 
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Only a few mtDNA pathologic point mutations account for the majority of cases. An 
interesting common feature of these mutations is that they are usually associated with very 
well-defined phenotypes, although some particular mtDNA mutations are associated with 
very different phenotypes. 
Epilepsy is also a frequent CNS manifestation of mitochondrial disorders (Abu-Amero KK, 
et al/2005; Patel MN, 2002; Tsuji M, et al. 2003). Epilepsy may start at infancy as infantile 
spasms (Blanco-Barca O. et al. 2004; Desguerre I, et al. 2003; Shah NS, et al. 2002), West 
syndrome (Tsuji M, et al. Blanco-Barca O. et al. 2004), myoclonic jerks (Van Goethem G, et 
al. 2003; Arenas J, et al. 1999; Casali C, et al. 1999), astatic seizures (Toyono M, et al. 2001), or 
juvenile myoclonic epilepsy (Minassian BA, et al.1995). In adultpatients myoclonic jerks or 
focal or generalized epilepsy may occur (Arenas J, et al. 1999;, Mitani M, et al. 2000). In 
single cases epilepsy a partial is continua have been reported (Balestri P, Grosso S. 2000). 
Epilepsy is particularly prevalent inpatients with MELAS, MERRF, LS, or NARP. 
Epidemiological studies have shown that epilepsy patients are more likely to have affected 
mothers than fathers. 
It is a well-known fact that epileptic seizures can be presenting signs of mitochondrial 
dysfunction in the central nervous system. Thus, generalized seizures have been observed in 
several forms of myoclonus epilepsy associated with mutations in the mitochondrial DNA 
polymerase Ǆ  (POLG) (Naviaux and Nguyen 2004; Zsurka et al. 2008), mitochondrial 
tRNALys (MT-TK) (Shoffner et al. 1990; Zeviani et al. 1993) and tRNAPhe (MT-TF) (Zsurka 
et al.2010) genes. Partial seizures are frequently noticed in mitochondrial encephalopathies, 
including the MELAS syndrome, associated with mutations in the mitochondrial tRNALeu 
gene (MT-TL1) (Goto et al. 1990). More recently, evidence for a more general involvement of 
mitochondria also in sporadic forms of epilepsy has been accumulated (Kann et al. 2005; 
Kunz et al. 2000; Kunz 2002). This might be related to the fact that mitochondria are 
intimately involved in pathways leading to neuronal cell death (Krajewski et al. 1999; 
Blümcke et al. 1999) as seen in experimental and human epilepsy. On the other hand, more 
recent data substantiate the evidence, that mitochondrial dysfunction might play a direct 
pathogenic role in the process of epileptogenesis and seizure generation in certain types of 
epilepsy. 
 
Syndrome PSY NPD SLE MIG EPI EPS SPS ATX HYP HRM DRT DPG NYS 
MELAS + + + + + - - + - + - - - 
MERRF + + + - + - + + - + + - - 
LS + + - + + + + + + - - - + 
LHON + - - - - + - - - - - - - 
KSS + + + - - - - + - + - + - 
NARP + + - - + - - + - - - - - 
CNS, central nervous system; PSY, psychiatric abnormalities; NPD, neuropsychological deficits; SLE, 
stroke-like-episodes; MIG, migraine; EPI, epilepsy; EPS, extrapyramidal manifestations; SPS, spasticity, 
hyperreflexia; ATX, ataxia; HYP, muscle hypotonia; HRM, hypopituitarism; DRT, dysarthria; DPG, 
dysphagia; NYS, nystagmus; MELAS, mitochondrial encephalomyopathy, lactic acidosis, stroke-like 
episodes; MERFF, myoclonic epilepsy and ragged red fibers; LS, Leigh syndrome, maternally inherited 
Leigh syndrome; LHON, Leber's hereditary optic neuropathy; KSS, Kearns-Sayre syndrome; NARP, 
neurogenic muscle, weakness, ataxia, and retinitis pigmentosa;  
Tabela 5. CNS manifestations of syndromic mitochondrial disease 
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The clinical syndrome was first recognized by Fukuhara et al.(1980), when he described 
the “canonical” signs of 1) myoclonus, 2) generalized tonic clonic and absence seizures, 3) 
ataxia, and 4) ragged red fibres in the muscle biopsy. MERRF usually starts in childhood 
but it is not uncommon in adults. Deafness in PME should make one consider MERRF, 
especially if dementia, dysarthria short stature, optic atrophy, neuropathy, lactic acidosis, 
hypoventilation, and migraine are present. Inheritance is consistent with mitochondrial 
(maternal) transmission. Muscle biopsy demonstrates subsarcolemmal aggregates of 
mitochondria, the so-called ragged-red Fibres. Giant visual evoked potentials are 
recorded in all cases. Shoffner et al. (1990) were the first to demonstrate the typical A-to-G 
substitution at nucleotide 8344 in the mitochondrial DNA, which affects the 
pseudouridine loop of the mitochondrial tRNALys. The A8344G mutation is present in 
90% of patients with MERRF. Two other mutations (T8356C and G8363A) in the tRNAlys 
gene have also been associated with MERRF. How these mutations produce the disease 
phenotype is unclear, although it is suspected to be a defect of oxidative energy 
production. 
 
Syndrome tRNA Protein
Single 
Deletion 
Multiple 
Deletion 
Duplication nDNA 
MELAS + + + + - - 
MERRF + - - + - + 
LS + + - - - + 
LHON - + - - - - 
KSS - - + + + - 
NARP - + - - - - 
MELAS, mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; MERFF, myoclonic 
epilepsy and ragged red fibers; LS, Leigh syndrome, maternally inherited Leigh syndrome; LHON, 
Leber's hereditary optic neuropathy; KSS, Kearns-Sayre syndrome; NARP, neurogenic muscle, 
weakness, ataxia, and retinitis pigmentosa;  
Table 6. Genetic heterogeneity of mitochondrial disease with CNS involvements 
MERRF syndrome is a devastating neuromuscular disorder characterized by myoclonic 
epilepsy, general weakness, muscle wasting, cerebellar ataxia, deafness, and dementia 
transmitted through maternal lineages (Shoffner JM et al 1990). Additional manifestations 
such as short stature, optic atrophy, peripheral neuropathy, cardiomyopathy, 
myoglobinuria, and renal tubular dysfunction have also been documented (ErolI  et al 2009) 
Common clinical manifestations include myopathy, neuropathy, hearing loss, dementia, 
short stature, and optic atrophy. Less commonly, cardiomyopathy, pigmentary retinopathy, 
pyramidal signs, ophthalmoparesis, multiple lipomas, and diabetes mellitus can occur. 
(Chinnery PF  et al. 1997)There is an overlap with the syndrome of MELAS, but MERRF 
usually has a longer course and is associated with milder behavioural and cognitive deficits. 
(DiMauro S et al. 2002) 
In patients with MERRF, the EEG shows generalised spike-and-wave discharges at 2–5 Hz, 
with background slowing that progress as the disease advances. Focal epileptiform 
discharges can also be seen.(So N. et al. 1989) Muscle biopsy shows ragged red fibres in over 
90% of patients.( Hirano M et al 1996) Biochemical studies of respiratory-chain enzymes in 
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muscle extracts usually show decreased activity.( Boulet L  et al. 1992) Besides, lactate and 
pyruvate are commonly elevated in serum at rest and increased excessively after moderate 
physical activities (Ozawa M et al 1995). Brain MRI may show brain atrophy and basal 
ganglia calcifications. (DiMauro S et al. 2002) Grey-matter signal changes on T2-weighted 
images are sometimes seen, with deep cerebral nuclei being more involved than the cerebral 
cortex. When signal changes are seen in the white matter, the peripheral white matter is the 
earliest to beinvolved. (BarkovichAJ et al 1993). When myoclonus and myoclonic seizures 
are combined with deafness, ataxia, and neuromyopathy, MERRF should be considered. 
 
 
Table 7. Spectrum of MERRF Syndrome 
Debilitating if not fatal, these epileptic encephalopathies are characterized by the triad of 
myoclonus, epilepsy, and progressive neurologic deterioration. Myoclonus or myoclonias 
consist of stimulus sensitive, segmental or par cellar, arrhythmic, and asynchronous lightning 
like muscular jerks that affect any muscle group in the body. Epilepsy is also stimulus sensitive 
and consists of generalized tonic± clonic or clonic±tonic±clonic seizures (grand mal) and 
absences. Neurologic deterioration consists of mental decline leading to dementia, cerebellar 
ataxia, and various progressive neurologic manifestations, depending on the cause. 
5. Genetics and diagnosis 
The most common molecular defect is an adenosine to guanine substitution at nucleotide 
pair 8344 (8344A→G) in the tRNALys gene of mitochondrial DNA. (Shoffner JM et al 
1990) Although few less frequent point mutations of mtDNA were also found in MERRF 
patients (Virgilio R et al 2009, and Blakely EL et al 2009). Besides, molecular genetic 
studies of several MERRF pedigrees and biochemical studies of skin fibroblasts showed a 
positive correlation between the A8344G mutation in the tRNALys gene of mtDNA and 
the reduction in the activities of respiratory enzyme Complexes I and IV (James AM et al. 
1996 and 1999). 
Another rare identified molecular cause of MERRF is a tyrosine to cytosine substitution 
(8356T→C) in the same gene, (Silvestri G et al. 1992) and another is a guanine to adenosine 
substitution (8363G→A). (Santorelli FM et. Al 1996) However, in some individuals, a 
mutation  has not been identified. Clinical clues to the presence of MERRF include deafness, 
optic atrophy, myopathy, lipomas, intrafamilial variation in age of onset, and maternal 
transmission. Ragged red fibres and mutations in germline DNA (eg, peripheral blood) can 
be used to confirm the diagnosis. (Hammans SR et al. 1991) 
Defects in mitochondrial respiratory enzyme Complexes I and IV accompanied with RRF 
are the most prominent biochemical defects in the muscle of MERRF patients (Antonická H 
et al 1999)  
www.intechopen.com
 
Novel Treatment of Epilepsy 48
 
Phenotype Mitochondrial gene Mutations References 
MELAS tRNALeu(UUR) A3243G, 
T3271C,A3252G, 
C3256T,A3260G, 
T3291C 
(Goto et al., 1990, 
1991,1994; Morten et al., 
1993;Nishino et al., 
1996;Sato et al., 1994) 
 tRNAPhe G583A  (Hanna et al., 1998) 
 tRNAVal G1642A (Taylor et al., 1996) 
 tRNAGln G4332A (Bataillard et al., 2001) 
 tRNACys A5814G (Manfredi et al., 1995) 
 tRNALys A8296G,T8316C, 
T8356C 
(Campos et al., 2000; 
Sakuta and Nonaka, 
1989; Zeviani et al., 
1993) 
 COX III T9957C (Manfredi et al., 1996) 
 ND5 G13513A (Santorelli et al., 1997) 
 ND6 G14453A (Ravn et al., 2001) 
 Cyt b del 14787-90 (De Coo et al., 1999) 
MERRF tRNALys A8344G, T8356C (Shoffner et al., 1990; 
Zeviani et al., 1993) 
 tRNAPhe G611A (Mancuso et al., 2004 
Atypical MERRF tRNALeu(UUR) G3255A (Nishigaki et al., 2003) 
 tRNASer(UCN 7472 Ins C (Pulkes et al., 2005) 
 tRNAAsp A7543G (Shtilbans et al., 1999) 
 tRNALys G8342A (Tiranti et al., 1999) 
 tRNAHis G12147A (Taylor et al., 2001) 
 ND3 T10191C (Taylor et al., 2004 
 ND5 G13042A (Naini et al., 2005) 
Seizures, PEO, 
diabetes, and deafness 
tRNALeu(UUR) A3256G (Moraes et al., 1993) 
Cardiomyopathy, 
deafness, and seizures 
tRNAIle A4269G, 
C4320T 
(Taniike et al., 1992; 
Santorelli et al., 1997) 
ME with recurrent 
episodes of epilepsia 
partialis continua 
tRNASer(UCN T7512C (Jaksch et al., 1998; 
Schuelke et al., 1998) 
 COX I C6489A (Varlamov et al., 2002) 
Leigh syndrome ATP6 T8993G,T8993C (Canafoglia et al., 2001; 
De Vries et al., 1993) 
 tRNALys G8363A (Shtilbans et al., 2000) 
LHON ND1 G3460A (Brown et al., 2001) 
 ND2 C4640A (Brown et al., 2001) 
ME — mitochondrial encephalopathy; MERRF — myoclonus epilepsy with ‘ragged redfibers’; MELAS 
— mitochondrial encephalopathy with lactic acidosis and stroke-likeepisodes; PEO — progressive 
external ophthalmoplegia; LHON — Leber's hereditaryoptical neuropathy; RC — respiratory chain.  
Table 8. Epileptic phenotypes in mitochondrial gene-related mitochondrial disorders. 
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Type of defect Biochemical defect Clinical phenotype Defective gene 
Genes altering the 
stability of 
mitochondrial DNA
mtDNA depletion Alpers syndrome POLG
 mtDNA depletion Infantile 
encephalopathy 
and hepatopathy
DGUOK 
 mtDNA depletion Infantile 
encephalomyopathy
SUCLG1 
 multiple mtDNA 
deletions
MNIGIE TYMP
Genes encoding 
structural  
components of 
OXPHOS  
complexes 
complex I 
deficiency 
 
Leigh syndrome or
encephalomyopathy 
 
NDUFS1, NDUFS2, 
NDUFS3, NDUFS4, 
NDUFS6, NDUFS7, 
NDUFS8, NDUFV1, 
NDUFV2 
 complex II 
deficiency
Leigh syndrome SDHA, SDHB,  
SDHC, SDHD 
Genes encoding 
assembly factors of 
OXPHOS complexes
complex I 
deficiency 
Encephalopathy NDUFA12 
 complex III 
deficiency 
Encephalopathy, 
tubulopathy 
and hepatopathy
BCS1L
 complex IV 
deficiency
Leigh syndrome SURF1
 complex IV 
deficiency
Infantile 
cardioencephalo-pathy
SCO2
 complex IV 
deficiency
Infantile encephalo-
pathy
SCO1, COX10 
Genes encoding 
factors involved in 
Transporter of 
carrier proteins
X-linked deafness-
dystonia syndrome
DDP1
the biogenesis of
mitochondria, 
including OXPHOS
Iron exporter X-linked 
ataxia/sideroblastic 
anemia syndrome
ABC7
 Iron storage protein Friedreich’s ataxia FRDA (Frataxin) 
 Metalloprotease, 
involved in protein 
turnover
Hereditary spastic 
paraplegia 
SPG7 (Paraplegin) 
 Dynamin-related 
protein, possibly 
involved in 
mitochondrial  
fission and fusion
Autosomal dominant 
optic atrophy 
OPA1
 
Table 9. Epilepsy phenotypes in patients with nuclear gene-related mitochondrial disorders 
Table modified according to M. Hirano et al. (2008). 
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Table 10. Clinical-genetic classification of mitochondrisl disorders. 
Mitochondrial dysfunction not only decreases the production of ATP but also increases the 
reactive oxygen species (ROS) generation through the electron leak from the respiratory 
chain in mitochondria (James AM et al. 1996 and 1999).  Consequently, enhanced oxidative 
stress and oxidative damage have been often observed in the affected tissues of MERRF 
patients (Bacman SR et al. 2003).  Normally, the expression and activity levels of antioxidant 
enzymes are induced to change so prevent cells from ROS-induced oxidative damage. Long-
term exposure to ROS of the affected cells in MERRF patients may initiate and expedite a 
vicious cycle to result in further increase of ROS production and enhanced oxidative 
damage to DNA, RNA, lipids, and proteins in mitochondria (Liu CY et al 2009). 
Nuclear disease genes associated with mitochondrial disease can be provisionally classified 
into four groups: (1) genes encoding structural components of OXPHOS complexes; (2) 
genes encoding assembly factors of OXPHOS complexes; (3) genes altering the stability of 
mitochondrial DNA; (4) genes encoding factors involved in the biogenesis of mitochondria, 
including OXPHOS. 
A8296G mutation was found in MT-TK and Ahadi et al (2008) suggest that this mutation is a 
rare polymorphism or may be a pathogenic mutation in combination with other mutations 
outside of the MT-TK gene. 
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6. Therapy  
Mitochondrial dysfunction has been identified as a potential cause of epileptic seizure and 
therapy-resistant forms of sere epilepsy. Experimental and human studies have suggested 
that excessive free radical generation and a deficient antioxidant system are directly or 
indirectly implicated as taking part in the pathogenesis of epilepsy, resulting in seizure 
recurrence and resistance to treatment with antiepileptic drugs. 
Antiepileptic drugs alter the neuronal oxidative status and increase membrane lipid 
peroxidation, leading to the increase risk of seizure recurrence. Epileptic patients and 
experimental animals with the antioxidant supplementations, such as vitamin E, melatonin 
and resveratrol, improve the oxidative damage in mitochondrial dysfunction. Hence, the 
antioxidant supply is beneficial for the prevention of mitochondrial dysfunction and 
recurrence of epilepsy. In addition, the detection of brain oxidative status is important for 
predicting the prognosis of patients with medication or surgery. 
In MERRF patients with secondary cytochrome-c oxidase deficiency intravenous 
administration of copper has been reported to be beneficial (Ohinata J, et al 2002). Seizures 
in mitochondrial diseases can be effectively treated with conventional antiepileptic drugs. If 
possible, however, valproate should be avoided because of its mitochondrial and liver 
toxicity and its hematological side effects. In addition, carbamazepine or oxcarbamazepine 
should be avoided because of its liver toxicity and its hematologic side effects, particularly 
in mitochondrial diseases patients who frequently also manifest with anemia, leucopenia, or 
thrombocytopenia. Furthermore, carbamazepine and oxcarbamazepine may cause or 
worsen hyponatriemia, and thus increase the risk of triggering further seizures. According 
to personal observations, topiramate may worsen wasting in mitochondrial diseases 
patients with myopathy. The most well tolerated antiepileptic drugs appear to be 
lamotrigine, gabapentin, lorazepam, and levetirazetam. For acute seizure control 
intravenous valproate is sometimes inevitable. Other options for intravenous antiepileptic 
acute therapy are lorazepam or phenytoin. In single cases with resistance to antiepileptic 
drugs succinate (6 g/day) may reduce seizure frequency. Uncinatus crises in MELAS can be 
effectively resolved with lorazempam. 
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